benanomicin B: from Actinomycete sp. MH193-16F4; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
pradimicin C : A member of the class of pradimicins that is isolated from the cultured broth of Actinomadura hibisca No. P157-2 (ATCC 53557). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5464366 |
| CHEBI ID | 8351 |
| SCHEMBL ID | 2228764 |
| MeSH ID | M0159230 |
| Synonym |
|---|
| benanomicin b |
| 116249-66-2 |
| pradimicin c |
| (2r)-2-[[(5s,6s)-5-[(2s,3r,4s,5s,6r)-5-amino-3-hydroxy-6-methyl-4-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]propanoic acid |
| d-alanine, n-((5-((4-amino-4,6-dideoxy-3-o-beta-d-xylopyranosyl-beta-d-galactopyranosyl)oxy)-5,6,8,13-tetrahydro-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxobenzo(a)naphthacen-2-yl)carbonyl)- |
| unii-2aey6x9qc2 |
| 2aey6x9qc2 , |
| (2r)-2-({[(5s,6s)-5-{[(2s,3r,4s,5s,6r)-5-amino-3-hydroxy-6-methyl-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yl]oxy}tetrahydro-2h-pyran-2-yl]oxy}-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenzo[a]tetracen-2-yl]ca |
| CHEBI:8351 |
| SCHEMBL2228764 |
| Q27108055 |
| d-alanine, n-(((5s,6s)-5-((4-amino-4,6-dideoxy-3-o-.beta.-d-xylopyranosyl-.beta.-d-galactopyranosyl)oxy)-5,6,8,13-tetrahydro-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxobenzo(a)naphthacen-2-yl)carbonyl)- |
| antibiotic bu-3608c |
| bu-3608c |
| n-(((5s,6s)-5-((4-amino-4,6-dideoxy-3-o-.beta.-d-xylopyranosyl-.beta.-d-galactopyranosyl)oxy)-5,6,8,13-tetrahydro-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxobenzo(a)naphthacen-2-yl)carbonyl)-d-alanine |
| 116249-66-2 (as free salt) |
| DTXSID001317618 |
| Class | Description |
|---|---|
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| disaccharide derivative | A carbohydrate derivative that is formally obtained from a disaccharide. |
| polyphenol | Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group. |
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| polyketide | Natural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides. |
| pradimicin | A class of antifungal bacterial metabolites whose structure is characterised by an aglycone of dihydrobenzonaphthacequinone with substitutions by a D-amino acid and a hexose sugar moiety. |
| L-alanine derivative | A proteinogenic amino acid derivative resulting from reaction of L-alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-alanine by a heteroatom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (26.67) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||